Article Text

PDF
A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes

Statistics from Altmetric.com

J F Mann

Dr J F Mann, Munich General Hospitals, Ludwig Maximilians University Munchen, Germany; johannes.mann@kms.mhn.de

STUDY DESIGN

Design:

randomised controlled trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial [ONTARGET]). ClinicalTrials.gov NCT00153101.

Allocation:

concealed.*

Blinding:

blinded (patients, clinicians, and {outcome assessors}†).*

STUDY QUESTION

Setting:

{733 centres in 40 countries.}†

Patients:

25 620 patients ⩾55 years of age who had established atherosclerotic vascular disease or diabetes with end-organ damage. At baseline, mean serum creatinine concentration was 94 μmol/l, mean estimated glomerular filtration rate (eGFR) was 74 ml/min/1.73 m2, and mean urine albumin-to-creatinine ratio (UACR) was 0.82 mg/mmol. Exclusion criteria included major renal artery stenosis, uncorrected volume or sodium depletion, serum creatinine concentration >265 μmol/l, and uncontrolled hypertension. …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.